Pfizer’s chief executive, Dr. Albert Bourla, said the drug-making company is in a “very advanced stage” and should know by the end of October whether the coronavirus vaccine they are ...

Pfizer has promoted Albert Bourla, seen as a likely successor to incumbent CEO Ian Read, to the newly-created role of chief operating officer. The move could help Read focus on long-term strategy ...

Pfizer’s CEO Ian Read is to step down after eight years and will be replaced on 1st January by chief operating officer Albert Bourla. In contrast to Merck & Co. which has rescinded a company ...

DAVOS, Switzerland—Albert Bourla has ambitious plans to turn around the situation at Pfizer. The market will decide if talk is cheap, but at least for now the stock looks cheap, or so the ...

Albert Bourla could be seen saying: "We know that the two doses of the vaccine offer very limited protection, if any." Jerome tweeted: "If this video is legit, it has to sound off some alarms ...

“Albert Bourla is very proud of his Greek heritage and of his Jewish heritage, from Thessaloniki,” the Israeli prime minister said. (JTA) — Israel’s government has signed an agreement with ...

High-protein cereal “can be a great alternative to donuts and baked goods, and it’s certainly an upgrade from Count Chocula,” says Kim Yawitz, R.D. Yes, you're probably better off with whole ...

The Collected Papers of Albert Einstein is one of the most ambitious publishing ventures ever undertaken in the documentation of the history of science. Providing the first assemblage and English ...

Microsoft co-founder Bill Gates can no longer count himself among the 10 wealthiest billionaires in the world, according to a Tuesday report from Forbes. SpaceX CEO Elon Musk slammed the FCC's ...

Pfizer’s CEO reflects on a year of discovery and what he thinks critics get wrong about vaccine pricing Albert Bourla talks about his employees' effort to develop a COVID-19 vaccine in record ...

Albert Bourla said Pfizer expects to price its treatment, called Paxlovid, close to where rival Merck & Co Inc has priced its oral antiviral drug candidate. The companies said the vaccine ...